- Home
- NYC vs SONN Comparison
NYC vs SONN Comparison
Compare NYC & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- SONN
- Stock Information
- Founded
- NYC 2013
- SONN N/A
- Country
- NYC United States
- SONN United States
- Employees
- NYC N/A
- SONN N/A
- Industry
- NYC Real Estate
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- SONN Health Care
- Exchange
- NYC Nasdaq
- SONN Nasdaq
- Market Cap
- NYC 28.8M
- SONN 24.2M
- IPO Year
- NYC N/A
- SONN N/A
- Fundamental
- Price
- NYC $10.35
- SONN $2.90
- Analyst Decision
- NYC
- SONN Strong Buy
- Analyst Count
- NYC 0
- SONN 1
- Target Price
- NYC N/A
- SONN $20.00
- AVG Volume (30 Days)
- NYC 1.6K
- SONN 557.9K
- Earning Date
- NYC 08-08-2025
- SONN 08-13-2025
- Dividend Yield
- NYC N/A
- SONN N/A
- EPS Growth
- NYC N/A
- SONN N/A
- EPS
- NYC N/A
- SONN N/A
- Revenue
- NYC $54,865,000.00
- SONN $1,000,000.00
- Revenue This Year
- NYC $8.40
- SONN $5,376.22
- Revenue Next Year
- NYC $1.62
- SONN N/A
- P/E Ratio
- NYC N/A
- SONN N/A
- Revenue Growth
- NYC N/A
- SONN 1689.52
- 52 Week Low
- NYC $7.89
- SONN $1.08
- 52 Week High
- NYC $16.30
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- NYC 36.47
- SONN 40.63
- Support Level
- NYC $9.53
- SONN $3.02
- Resistance Level
- NYC $10.96
- SONN $3.80
- Average True Range (ATR)
- NYC 0.73
- SONN 0.31
- MACD
- NYC -0.13
- SONN -0.03
- Stochastic Oscillator
- NYC 23.63
- SONN 1.96
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.